Subscribe to RSS
DOI: 10.1055/s-0045-1811699
Imaging Capabilities of Patients with Early-stage Collagenoses
Authors
Abstract
The general term collagenosis covers a group of connective tissue diseases triggered by systemic autoimmune processes and as yet unknown trigger mechanisms. Systemic sclerosis is one of the five types of collagenosis. Of the systemic rheumatic diseases, it has the highest mortality rate, partly due to the historical lack of disease-modifying therapies. Early diagnosis of systemic sclerosis can be challenging if the typical symptoms and diagnostic or classification criteria are not yet evident. However, given the disease's often heterogeneous course, early diagnosis and treatment are crucial for prognosis and to protect against progression involving the internal organs. Because reliable and prognostically valid biomarkers are generally lacking, deciding whether or not to pursue aggressive treatment in the early stages of the disease remains problematic. This article discusses the potential benefits of imaging techniques such as magnetic resonance imaging and pharmacoangiography for the early diagnosis of systemic sclerosis.
Keywords
collagenoses - systemic sclerosis - early diagnosis - magnetic resonance imaging - pharmacoangiographyPublication History
Article published online:
03 December 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Masi AT. et al. Preliminary criteria of the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23 (05) 581-590
- 2 LeRoy EC, Black C, Fleischmajer R. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15 (02) 202-205
- 3 van den Hoogen F, Khanna D, Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72 (11) 1747-1755
- 4 Raynaud M. De l'asphyxie locale de la gangrène symétrique des extrémities [Local asphyxia and symmetrical gangrene of the extremities]. Paris, France: L. Leclerc, Rignaux; 1862
- 5 Zuber M, Koch B, Gause A, Pfreundschuh M. Diagnose- und Klassifikationskriterien in der Rheumatologie: Kollagenosen. Dtsch Med Wochenschr 1996; 121 (28–29): 913-918
- 6 Denton CP, Khanna D. Systemic sclerosis. Lancet 2017; 390 (10103): 1685-1699
- 7 XDu A, Osman M, Gniadecki R. Use of extracorporeal photopheresis in scleroderma: a review. Dermatology 2020; 236 (02) 105-110
- 8 Schinke S, Riemekasten G. Systemische sklerose. Internist (Berl) 2019; 60 (12) 1251-1269
- 9 Knobler R, Moinzadeh P, Hunzelmann N. et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol 2017; 31 (09) 1401-1424
- 10 Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953–1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15 (02) 276-283
- 11 Knobler R, Arenberger P, Arun A. et al. European dermatology forum-updated guidelines on the use of extracorporeal photopheresis 2020, part 1. J Eur Acad Dermatol Venereol 2020; 34 (12) 2693-2716
- 12 Yune HY, Vix VA, Klatte EC. Early fingertip changes in scleroderma. JAMA 1971; 215 (07) 1113-1116
- 13 Arslan Tas D, Erken E, Sakalli H, Yucel AE. Evaluating hand in systemic sclerosis. Rheumatol Int 2012; 32 (11) 3581-3586
- 14 Avouac J, Guerini H, Wipff J. et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 2006; 65 (08) 1088-1092
- 15 Dabich L, Bookstein JJ, Zweifler A, Zarafonetis CJ. Digital arteries in patients with scleroderma. Arteriographic and plethysmographic study. Arch Intern Med 1972; 130 (05) 708-714
- 16 Janevski B. Arteries of the hand in patients with scleroderma. Diagn Imaging Clin Med 1986; 55 (4-5): 262-265
- 17 Hasegawa M, Nagai Y, Tamura A, Ishikawa O. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 2006; 155 (06) 1159-1164
- 18 Allanore Y, Seror R, Chevrot A, Kahan A, Drapé JL. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum 2007; 56 (08) 2747-2754
- 19 Hughes M, Di Donato S, Gjeloshi K. et al. MRI Digital Artery Volume Index (DAVIX) as a surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis: a prospective cohort study. Lancet Rheumatol 2023; 5 (10) e611-e621
- 20 Clifford PC, Martin MF, Dieppe PA, Sheddon EJ, Baird RN. Prostaglandin E1 infusion for small vessel arterial ischaemia. J Cardiovasc Surg (Torino) 1983; 24 (05) 503-508
- 21 Pardy BJ, Hoare MC, Eastcott HH. et al. Prostaglandin E1 in severe Raynaud's phenomenon. Surgery 1982; 92 (06) 953-965
- 22 Chitale S, Ciapetti A, Hodgson R. et al. Magnetic resonance imaging and musculoskeletal ultrasonography detect and characterize covert inflammatory arthropathy in systemic sclerosis patients with arthralgia. Rheumatology (Oxford) 2010; 49 (12) 2357-2361
- 23 Wolf M, Montesi SB. Novel imaging strategies in systemic sclerosis. Curr Rheumatol Rep 2020; 22 (09) 57
- 24 Smitaman E, Pereira BP, Huang BK, Zakhary MM, Fliszar E, Resnick DL. Abnormal bone marrow signal intensity in the phalanges of the foot as a manifestation of Raynaud phenomenon: a report of six patients. AJR Am J Roentgenol 2016; 207 (06) 1252-1256
- 25 Markousis-Mavrogenis G, Bournia VK, Sfikakis PP, Mavrogeni SI. Raynaud phenomenon and microvasculopathy in systemic sclerosis: multi-modality imaging for diagnosis and evaluation. Curr Opin Rheumatol 2023; 35 (06) 324-333
- 26 Rutka K, Garkowski A, Karaszewska K, Łebkowska U. Imaging in diagnosis of systemic sclerosis. J Clin Med 2021; 10 (02) 248
- 27 Bukiri H, Volkmann ER. Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol 2022; 64: 102211
- 28 Tashkin DP, Elashoff R, Clements PJ. et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354 (25) 2655-2666
- 29 Tashkin DP, Roth MD, Clements PJ. et al; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4 (09) 708-719
- 30 Namas R, Tashkin DP, Furst DE. et al; Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res (Hoboken) 2018; 70 (03) 439-444
- 31 van Laar JM, Farge D, Sont JK. et al; EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311 (24) 2490-2498
- 32 Sullivan KM, Goldmuntz EA, Keyes-Elstein L. et al; SCOT Study Investigators. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018; 378 (01) 35-47
- 33 Viswanath V, Phiske MM, Gopalani VV. Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol 2013; 58 (04) 255-268
- 34 Lambrecht R, Heinrich P, Ladetzki HH, Morenz J. Clinical, immunologic and therapeutic aspects of endangiitis obliterans. [in German]. Z Gesamte Inn Med Ihre Grenzgeb 1988; 43 (18) 511-514
- 35 Fiehn C. Familiärer Chilblain-Lupus. Z Rheumatol 2017; 76: 322-327
- 36 da Silva LNM, Guimarães JB, Link TM. et al. Prevalence of phalangeal bone marrow edema on MRI before and during the COVID-19 pandemic and correlation with chilblain skin lesions. Skeletal Radiol 2023; 52 (09) 1721-1728
- 37 Dihlmann W. Acquired hyperostosis syndrome (so-called pustular arthro-osteitis). Review of the literature including 73 personal cases. [in German]. Wien Klin Wochenschr 1993; 105 (05) 127-138
